<SEC-DOCUMENT>0001654954-25-005296.txt : 20250508
<SEC-HEADER>0001654954-25-005296.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508172619
ACCESSION NUMBER:		0001654954-25-005296
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20250507
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954078884
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15543
		FILM NUMBER:		25927520

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ptn_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:ptn="http://ptn.com/20250507"><head><title>ptn_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2025-05-07to2025-05-07" id="ixv-467">0000911216</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2025-05-07to2025-05-07" format="ixt:booleanfalse" id="ixv-468">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptn-20250507.xsd"/></ix:references><ix:resources><xbrli:context id="From2025-05-07to2025-05-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-07</xbrli:startDate><xbrli:endDate>2025-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:DocumentType" id="ixv-488">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CURRENT REPORT</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported): <strong><span style="text-decoration:underline"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" id="ixv-489">May 7, 2025</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityRegistrantName" id="ixv-490">PALATIN TECHNOLOGIES, INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-491">Delaware</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityFileNumber" id="ixv-492">001-15543</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityTaxIdentificationNumber" id="ixv-493">95-4078884</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Commission</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS employer</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of incorporation)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">File Number)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">identification number)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityAddressAddressLine1" id="ixv-494">4B Cedar Brook Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityAddressCityOrTown" id="ixv-495">Cranbury</ix:nonNumeric>, <ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityAddressStateOrProvince" id="ixv-496">NJ</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityAddressPostalZipCode" id="ixv-497">08512</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant's telephone number, including area code: <strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:CityAreaCode" id="ixv-498">609</ix:nonNumeric>) <ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:LocalPhoneNumber" id="ixv-499">495-2200</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">Not Applicable</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="ixv-500">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="ixv-501">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="ixv-502">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="ixv-503">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Symbol</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of Each Exchange</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>on Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:Security12bTitle" id="ixv-504">Common Stock, par value $0.01 per share</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:TradingSymbol" id="ixv-505">PTN</ix:nonNumeric></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-506">NYSE</ix:nonNumeric> American</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Emerging growth company <ix:nonNumeric contextRef="From2025-05-07to2025-05-07" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-507">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 1.01 Entry into a Material Definitive Agreement.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 7, 2025, Palatin Technologies, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with institutional investors named on the signature pages thereto pursuant to which the Company agreed to sell and issue, in a reasonable best efforts registered public offering (the &#8220;Offering&#8221;), an aggregate of 76,666,667 shares of common stock, $0.01 par value per share, of the Company (the &#8220;Shares&#8221;) of which also consisted of common stock equivalents in lieu thereof, series f common warrants (the &#8220;Series F Common Warrants&#8221;) to purchase up to 76,666,667 shares of the Company&#8217;s common stock (the &#8220;Series F Warrant Shares&#8221;), series g common warrants (the &#8220;Series G Common Warrants&#8221;) to purchase up to 76,666,667 shares of the Company&#8217;s common stock (the &#8220;Series G Warrant Shares&#8221;), and series h common warrants (the &#8220;Series H Common Warrants&#8221; and together with the Series F Common Warrants and Series G Common Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 76,666,667 shares of the Company&#8217;s common stock (the &#8220;Series H Warrant Shares&#8221; and together with the Series F Warrants Shares and Series G Warrant Shares, the &#8220;Common Warrant Shares&#8221;). The Shares were offered at an offering price of $0.15 per Share. The Common Warrants were offered concurrently with the Shares. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Series F Common Warrants will have an exercise price of&#160;$0.30&#160;per share, will be immediately exercisable and will expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such Series F Common Warrant. The Series G Common Warrants will have an exercise price of&#160;$0.15&#160;per share, will be immediately exercisable and will expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Common Warrant). The Series H Common Warrants will be issuable to the holder upon their exercise of the Series G Common Warrants, will have an exercise price of&#160;$0.225&#160;per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The gross proceeds from the Offering, after deducting the placement agent fees and offering expenses, were expected to be $11.5 million. The Company intends to use the net proceeds received from the Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As described in more detail in Item 3.01 below, after the Purchase Agreement was executed, on May 7, 2025 the Company received notice from NYSE Regulation that it had suspended trading of the Company&#8217;s common stock on the NYSE American LLC stock exchange (&#8220;NYSE American&#8221;). Subsequently, also on May 7, 2025, the Company issued a press release discussing matters disclosed in Item 3.01 below. A copy of such press release is attached as Exhibit 99.1 and is incorporated herein by reference. Also on May 7, 2025, certain investors notified the Company that an event listed under Section 2.3(b)(v) of the Purchase Agreement had occurred and that such investors would not proceed to closing in connection with the Offering.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As a result, on May 8, 2025, the Company raised approximately $1.1 million in net proceeds from the reduced Offering. The Company intends to use the net proceeds received from the Offering for general working capital purposes.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The securities were offered and sold pursuant to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-286280) previously filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) and declared effective on May 6, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Purchase Agreement contains representations and warranties that the parties made to, and solely for the benefit of, each other in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between the parties. The Purchase Agreement also contains customary conditions to closing, termination rights of the parties, certain indemnification obligations of the Company and ongoing covenants for the Company, including a prohibition on the Company&#8217;s sale and issuance of additional securities for a period of 45 days from the closing date of the Offering and entering into variable rate transactions (as defined in the Purchase Agreement) for a period of 4 months from the closing date of the Offering, subject to certain exceptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A holder (together with its affiliates) may not exercise any portion of the Common Warrants to the extent that the holder would own more than 9.99% (or, at the holder&#8217;s option upon closing of the Offering, 4.99%) of the number of shares of the Company&#8217;s outstanding common stock immediately after exercise. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder to us and such increase or decrease will apply only to the holder providing such notice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 7, 2025, the Company entered into a placement agency agreement (the &#8220;Placement Agent Agreement&#8221;) with A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), as lead placement agent and Laidlaw &amp; Company (UK) Ltd., as co-placement agent (&#8220;Laidlaw,&#8221; and together with A.G.P., the &#8220;Placement Agents&#8221;), pursuant to which the Company engaged A.G.P. and Laidlaw as the exclusive placement agents in connection with the Offering. The Company agreed to pay the Placement Agents a fee in cash equal to 7.00% of the gross proceeds from the sale of the Shares and Common Warrants. The Company also agreed to reimburse the Placement Agents for out-of-pocket expenses, including the reasonable fees of legal counsel not to exceed $85,000. The Placement Agent Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Offering is expected to close on May 8, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The descriptions of terms and conditions of the Purchase Agreement, the Series F Common Warrants, the Series G Common Warrants, the Series H Common Warrants, and the Placement Agency Agreement set forth herein do not purport to be complete and are qualified in their entirety by the full text of the form of Purchase Agreement, the form of Series F Common Warrant, the form of Series G Common Warrant, the form of Series H Common Warrant, and the form of Placement Agency Agreement, which are attached hereto as Exhibits 10.1, 4.1, 4.2, 4.3 and 1.1, respectively, and incorporated herein by reference. Accordingly, the Purchase Agreement and Placement Agency Agreement are incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement and Placement Agency Agreement and not to provide investors with any other factual information regarding the Company or its business and investors and the public should look to other disclosures contained in the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) for any other such factual information.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Current Report on Form 8-K does not constitute an offer to sell the securities or a solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 7, 2025, the Company received notice from NYSE Regulation that it had suspended trading of the Company&#8217;s common stock on the NYSE American LLC stock exchange (&#8220;NYSE American&#8221;) and determined to commence proceedings to delist the Company&#8217;s common stock from the NYSE American as a result of its determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#8217;s common stock. Trading of the Company&#8217;s common stock on the NYSE American was suspended on May 7, 2025 and began trading on the OTC Pink Market on May 8, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has a right to a review of NYSE Regulation&#8217;s determination to delist the Company&#8217;s common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The Company is currently assessing the viability of such an appeal.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NYSE Regulation&#8217;s notice also stated that the Company remains subject to the delisting letter dated April 10, 2025 in relation to the NYSE American Company Guide commencing delisting procedures against the Company pursuant to Section 1009(a) of the NYSE American Company Guide as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 8.01 Other Events.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 7, 2025, the Company issued a press release discussing matters disclosed in Item 3.01 above. A copy of such press release is attached as Exhibit 99.1 and is incorporated herein by reference. Also on May 7, 2025, the Company issued a press release announcing the Offering. A copy of such press release is attached as Exhibit 99.2 and is incorporated herein by reference.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;indicates,&#8221; &#8220;will,&#8221; &#8220;intends,&#8221; &#8220;potential,&#8221; &#8220;suggests,&#8221; &#8220;assuming,&#8221; &#8220;designed&#8221; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations and involve certain risks and uncertainties, including the quotation of the Company&#8217;s common stock on the OTC Pink Market, the Company&#8217;s appeal or ability to appeal the delisting of the Company&#8217;s common stock by NYSE Regulation, and statements regarding the expected net proceeds of the Offering. Additional information and key risks applicable to these statements are described in the Company&#8217;s reports on Forms 8-K, 10-Q and 10-K and other filings the Company makes with the Securities and Exchange Commission. All of the forward-looking statements in this Current Report on Form 8-K are qualified by these cautionary statements, and actual results or developments may differ materially from those in these forward-looking statements. The Company assumes no obligation to publicly update or revise any forward-looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 9.01 Financial Statements and Exhibits.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(d) Exhibits:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex11.htm">1.1</a></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex11.htm">Form of Placement Agency Agreement, dated May 7, 2025, by and between the Company, A.G.P./Alliance Global Partners, and Laidlaw &amp; Company (UK) Ltd.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex41.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex41.htm">Form of Series F Common Warrant</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex42.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex42.htm">Form of Series G Common Warrant</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex43.htm">4.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex43.htm">Form of Series H Common Warrant</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex101.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex101.htm">Form of Securities Purchase Agreement, dated May 7, 2025, by and between the Company and the Purchasers named therein.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex991.htm">Press Release, dated May 7, 2025.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex992.htm">99.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="ptn_ex992.htm">Press Release, dated May 7, 2025.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cover Page Interactive Data File (formatted as Inline XBRL)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">PALATIN TECHNOLOGIES, INC.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 8, 2025</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Stephen T. Wills </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen T. Wills, CPA, MST</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Executive Vice President, Chief Financial Officer </p><p style="font-size:10pt;font-family:times new roman;margin:0px">and Chief Operating Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ptn_ex11.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT
<TEXT>
<html><head><title>ptn_ex11.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 1.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>A.G.P./Alliance Global Partners</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>590 Madison Avenue, 28th Floor</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>New York, NY 10022</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">and</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Laidlaw &amp; Company (UK) Ltd.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>521 5th Ave,</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>New York, NY 10175</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 7, 2025</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Palatin Technologies, Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">4B Cedar Brook Drive</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Cranbury, New Jersey 08512</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Attention: Carl Spana, Ph.D., President and Chief Executive Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Re:</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>Placement Agency Agreement</u></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dear Dr. Spana:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Subject to the terms and conditions of this letter agreement (the &#8220;<strong>Agreement</strong>&#8221;) between A.G.P./Alliance Global Partners (the &#8220;<strong>Lead Placement Agent</strong>&#8221;) and Laidlaw &amp; Company (UK) Ltd. (the &#8220;<strong>Co-Placement Agent</strong>&#8221; and together with the Lead Placement Agent, the &#8220;<strong>Placement Agents</strong>&#8221;) and Palatin Technologies, Inc., a Delaware corporation (the &#8220;<strong>Company</strong>&#8221;), the parties hereby agree that the Placement Agents shall serve as the exclusive placement agents for the Company, on a &#8220;reasonable best efforts&#8221; basis, in connection with the proposed placement (the &#8220;<strong>Placement</strong>&#8221;) of securities of the Company, consisting of: (i)&nbsp;registered shares (the &#8220;<strong>Shares</strong>&#8221;) of common stock, par value $0.01 per share (&#8220;<strong>Common Stock</strong>&#8221;); (ii) registered pre-funded warrants to purchase shares of Common Stock (the &#8220;<strong>Pre-Funded Warrants</strong>&#8221;); and (iii) registered warrants to purchase Common Stock (the &#8220;<strong>Common Warrants</strong>&#8221; and together with the Pre-Funded Warrants and the Shares, the &#8220;<strong>Securities</strong>&#8221;).&nbsp; The Securities actually placed by the Placement Agents are referred to herein as the &#8220;<strong>Placement Agent Securities</strong>.&#8221;&nbsp; The Shares, the Common Warrants, the Pre-Funded Warrants and the Common Stock underlying the Common Warrants and Pre-Funded Warrants will be offered and sold under the Company&#8217;s registration statement on Form S-1 (File No. 333- 286280). The documents executed and delivered by the Company and the Purchasers (as defined below) in connection with the Placement, including, without limitation, a securities purchase agreement (the &#8220;<strong>Purchase</strong>&nbsp;<strong>Agreement</strong>&#8221;), shall be collectively referred to herein as the &#8220;<strong>Transaction Documents</strong>.&#8221;&nbsp; The terms of the Placement shall be mutually agreed upon by the Company and the purchasers listed in the Purchase Agreement (each, a &#8220;<strong>Purchaser</strong>&#8221; and collectively, the &#8220;<strong>Purchasers</strong>&#8221;), and nothing herein constitutes that the Placement Agents would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company to issue any Placement Agent Securities or complete the Placement.&nbsp; The Company expressly acknowledges and agrees that the Placement Agents&#8217; obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agents to purchase the Placement Agent Securities and does not ensure the successful placement of the Placement Agent Securities or any portion thereof or the success of the Placement Agents with respect to securing any other financing on behalf of the Company.&nbsp; The Placement Agents may retain other brokers or dealers to act as sub-agents or selected-dealers on their behalf in connection with the Placement; provided, however, that the Company shall first approve any such sub-agents or selected-dealers.&nbsp; Certain affiliates of the Placement Agents may participate in the Placement by purchasing some of the Placement Agent Securities.&nbsp; The sale of Placement Agent Securities to any Purchaser will be evidenced by the Purchase Agreement between the Company and such Purchaser, in a form reasonably acceptable to the Company and the Purchaser.&nbsp; Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.&nbsp; Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from prospective Purchasers. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 1. </u><u>REPRESENTATIONS AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">A.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Representations of the Company</u>. With respect to the Placement Agent Securities, each of the representations and warranties (together with any related disclosure schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing Date, hereby made to, and in favor of, the Placement Agents. In addition to the foregoing, the Company represents and warrants that there are no affiliations with any Financial Industry Regulatory Authority (&#8220;<strong>FINRA</strong>&#8221;) member firm participating in the Placement among the Company&#8217;s officers, directors or, to the knowledge of the Company, any five percent (5.0%) or greater stockholder of the Company, except as set forth in the Purchase Agreement.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B.&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Covenants of the Company</u>. The Company covenants and agrees that except for an Exempt Issuance (as defined in the Purchase Agreement) or as otherwise provided for in the Purchase Agreement, from the date hereof until forty-five (45) days following the Closing Date (the &#8220;<strong>Restriction Period</strong>&#8221;), neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus Supplement, or a registration statement on Form S-8 in connection with any equity incentive plan. In addition, from the date hereof until four (4) months after the Closing Date, neither the Company nor any Subsidiary shall effect or enter into an agreement to effect any issuance by the Company or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) (or a combination of units thereof) involving a Variable Rate Transaction (as defined in the Purchase Agreement). Notwithstanding the foregoing, this Section 1(B) shall not apply with respect to an Exempt Issuance and, after fifteen (15) days following the Closing Date, the issuance of shares of Common Stock in an &#8220;at the market&#8221; offering under that certain Sales Agreement by and between the Company and the Lead Placement Agent dated February 11, 2025, shall not be deemed a Variable Rate Transaction and the Company may file any related prospectus supplement thereto.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 2.</u><u>REPRESENTATIONS OF THE PLACEMENT AGENTS</u>. The Placement Agents each represent and warrant that it: (i) is a member in good standing of FINRA, (ii) is registered as a broker/dealer under the Securities Exchange Act of 1934, as amended (the &#8220;<strong>Exchange Act</strong>&#8221;), (iii) is licensed as a broker/dealer under the laws of the United States of America, applicable to the offers and sales of the Placement Agent Securities by the Placement Agents, (iv) is and will be a corporate body validly existing under the laws of its place of incorporation, and (v) has full power and authority to enter into and perform its obligations under this Agreement. The Placement Agents will immediately notify the Company in writing of any change in their status with respect to subsections (i) through (v) above. Each of the Placement Agents covenants that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 3. </u><u>COMPENSATION</u>. In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agents and/or its designees total cash fee equal to seven percent (7.0%) of gross proceeds from the Placement of the total amount of Placement Agent Securities sold <em>provided, however</em>, for those investors identified on Schedule 1 hereof, the Company shall only pay a cash fee of four percent (4.0)% of the aggregate gross proceeds invested by such investors. The Placement Agents reserve the right to reduce any item of compensation, including the reimbursement of expenses described in Section 4 below, or adjust the terms thereof as specified herein in the event that a determination shall be made by FINRA to the effect that the Placement Agents&#8217; aggregate compensation is in excess of FINRA Rules or that the terms thereof require adjustment.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 4. </u><u>EXPENSES</u>. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Placement Agent Securities (including all printing and engraving costs); (ii) all fees and expenses of the transfer agent; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Placement Agent Securities; (iv) all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts) and the Prospectus, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&#8217; fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Placement Agent Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country; (vii) the fees and expenses associated with including the Placement Agent Securities on the Trading Market; and (viii) up to $85,000 for accountable expenses related to legal fees of external counsel to the Placement Agents.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 5. </u>[Reserved]. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 6. </u><u>INDEMNIFICATION</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">A.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the extent permitted by law, with respect to the Placement Agent Securities, the Company will indemnify the Placement Agents and each of their respective affiliates, stockholders, directors, officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of their activities hereunder or pursuant to this Agreement, except to the extent that any losses, claims, damages, expenses or liabilities (or actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have resulted primarily from the Placement Agents&#8217; bad faith, willful misconduct or gross negligence in performing the services described herein.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">B.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Promptly after receipt by a Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which such Placement Agent is entitled to indemnity hereunder, such Placement Agent will notify the Company in writing of such claim or of the commencement of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects or is requested by a Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel reasonably satisfactory to such Placement Agent and will pay the reasonable fees and expenses of such counsel. Notwithstanding the preceding sentence, the Placement Agents will be entitled to employ its own counsel separate from counsel for the Company and from any other party in such action if counsel for the Placement Agents reasonably determines that it would be conflict of interest under the applicable rules of professional responsibility for the same counsel to represent both the Company and the Placement Agents. In such event, the reasonable fees and disbursements of no more than one such separate counsel will be paid by the Company, in addition to reasonable fees of local counsel. The Company will have the right to settle the claim or proceeding provided that the Company will not settle any such claim, action or proceeding without the prior written consent of the Placement Agents, which will not be unreasonably withheld. The Company shall not be liable for any settlement of any action effected without its written consent, which will not be unreasonably withheld.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company agrees to notify the Placement Agents promptly of the assertion against it or any other person of any claim or the commencement of any action or proceeding relating to a transaction contemplated by this Agreement.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If for any reason the foregoing indemnity is unavailable to the Placement Agents or insufficient to hold the Placement Agents harmless (other than due to the express provisions thereof), then the Company shall contribute to the amount paid or payable by the Placement Agents as a result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Placement Agents on the other, but also the relative fault of the Company on the one hand and the Placement Agents on the other that resulted in such losses, claims, damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the Placement Agents&#8217; share of the liability hereunder shall not be in excess of the amount of fees actually received, or to be received, by the Placement Agents under this Agreement (excluding any amounts received as reimbursement of expenses incurred by the Placement Agents).</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These indemnification provisions shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall survive the termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party under this Agreement or otherwise.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 7. </u><u>ENGAGEMENT TERM</u>. The Placement Agents&#8217; engagement hereunder will be until the earlier of the Closing Date and April 25, 2025 (the &#8220;<strong>Term</strong>&#8221;). The date of termination of this Agreement is referred to herein as the &#8220;<strong>Termination Date</strong>.&#8221; In the event, however, in the course of the Placement Agents&#8217; performance of due diligence they deem it necessary to terminate the engagement, the Placement Agents may do so prior to the Termination Date. The Company may elect to terminate the engagement hereunder for any reason prior to the Termination Date but will remain responsible for fees pursuant to Section 3 hereof with respect to the Placement Agent Securities if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning the Company&#8217;s obligation to pay any fees actually earned pursuant to Section 3 hereof and the provisions concerning confidentiality, indemnification and contribution contained herein, as well as provisions in Sections 9 and 11 hereof will survive any expiration or termination of this Agreement. If this Agreement is terminated prior to the completion of the Placement, all fees and expenses due to the Placement Agents as set forth in Section 3 and Section 4 shall be paid by the Company to the Placement Agents on or before the Termination Date (in the event such fees are earned or owed as of the Termination Date). The Placement Agents agree not to use any confidential information concerning the Company provided to the Placement Agents by the Company for any purposes other than those contemplated under this Agreement.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 8. </u><u>PLACEMENT AGENTS&#8217; INFORMATION</u>. The Company agrees that any information or advice rendered by the Placement Agents in connection with this engagement is for the confidential use of the Company only in its evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without the Placement Agents&#8217; prior written consent.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 31.5pt; text-align:justify;"><u>SECTION 9. </u><u>NO FIDUCIARY RELATIONSHIP</u>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that the Placement Agents are not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agents hereunder, all of which are hereby expressly waived.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 10. </u><u>CLOSING</u>. The obligations of the Placement Agents, and the closing of the sale of the Placement Agents Securities hereunder are subject to the accuracy, when made and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase Agreement, to the performance by the Company of its obligations hereunder and in the Purchase Agreement, and to each of the following additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agents:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">A.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement Agent Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement Agent Securities shall be reasonably satisfactory in all material respects to the Placement Agents.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents shall have received from Company Counsel, such counsel&#8217;s written legal opinion with respect to the Placement Agent Securities in form and substance reasonably satisfactory to the Placement Agents.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents shall have received executed Lock-Up Agreements from the Company&#8217;s executive officers and directors.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The class of Common Stock sold in the Placement, including shares of Common Stock issuable upon the exercise of the Common Warrants, must be registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the effect of, terminating the registration of such class of Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing, except as disclosed in the Registration Statement and the Prospectus.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date, prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">F.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company shall have entered into a Purchase Agreement with each of the Purchasers of the Placement Agent Securities and such agreements shall be in full force and effect and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall, if requested by the Placement Agents, make or authorize Placement Agents&#8217; counsel to make on the Company&#8217;s behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing fees required in connection therewith.</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">H.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Placement Agents shall have received customary certificates from one or more of the Company&#8217;s executive officers, as to the accuracy of the representations and warranties contained in the Purchase Agreement, a certificate executed by the Chief Financial Officer of the Company, in form and substance reasonably acceptable to the Placement Agents and a certificate of the Company&#8217;s secretary certifying (i) that the Company&#8217;s charter documents are true and complete, have not been modified and are in full force and effect; (ii) that the resolutions of the Company&#8217;s Board of Directors relating to the Placement are in full force and effect and have not been modified; and (iii) as to the incumbency of the officers of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">If any of the conditions specified in this Section 10 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agents hereunder may be cancelled by the Placement Agents at, or at any time prior to, the Closing Date. Notice of such cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 11. </u><u>GOVERNING LAW</u>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely in such State, without regard to principles of conflicts of law thereof that would require the application of the laws of any other jurisdiction. This Agreement may not be assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney&#8217;s fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 12. </u><u>ENTIRE AGREEMENT/MISCELLANEOUS</u>. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both the Placement Agents and the Company. The representations, warranties, agreements and covenants contained herein shall survive the Closing Date of the Placement and delivery of the Placement Agent Securities. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 13. </u><u>NOTICES</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the e-mail address specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication is sent to the e-mail address on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following the date of mailing, if sent by an internationally recognized air courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;"><u>SECTION 14. </u><u>PRESS ANNOUNCEMENTS</u>. The Company agrees that the Placement Agents shall, on and after the Closing Date, have the right to reference the Placement and the Placement Agents&#8217; role in connection therewith in the Placement Agents&#8217; marketing materials and on their websites and to place advertisements in financial and other newspapers and journals, in each case at their own expense and in compliance with applicable securities laws.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">Please confirm that the foregoing correctly sets forth our agreement by signing and returning to the Placement Agents the enclosed copy of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><em>[The remainder of this page has been intentionally left blank.]</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">The foregoing Agreement is hereby accepted and agreed to as of the date first written above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>A.G.P./ALLIANCE GLOBAL PARTNERS</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ Thomas J. Higgins</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;">Thomas J. Higgins</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td style="vertical-align:top;">Managing Director</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Address for Notice:</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">590 Madison Avenue, 28<sup style="vertical-align:super">th</sup> Floor</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">New York, NY 10022</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Attn: Thomas J. Higgins</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">E-mail: </td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LAIDLAW &amp; COMPANY (UK) LTD.</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;">/s/ /s/ Luke Kottke</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;">Luke Kottke</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td style="vertical-align:top;">Head of Capital Markets</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Address for Notice:</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">521 5th Avenue</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">New York, NY 10175</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">Attn:</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;">E-mail:</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accepted and agreed to as of the date first written above:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;">/s/ Stephen T. Wils, CPA, MST</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name:</p></td> <td style="vertical-align:top;">Stephen T. Wills, CPA, MST</td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title:</p></td> <td colspan="2" style="vertical-align:top;">Executive Vice President, Chief Financial Officer and Chief Operating Officer</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><u>Address for Notice</u>:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Palatin Technologies, Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">4B Cedar Brook Drive</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Cranbury, New Jersey 08512</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Attention: Carl Spana, Ph.D., President and Chief Executive Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">E-mail:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">With a copy (which shall not constitute notice) to:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Thompson Hine LLP</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">300 Madison Avenue, 27th Floor</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">New York, New York 10017-6232</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Attention: Faith Charles, Esq.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">E-mail:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><em>[Signature Page to Placement Agency Agreement]</em> </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ptn_ex41.htm
<DESCRIPTION>SERIES F COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex41.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES F COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Warrant Shares: [&#8226;]</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">Issue Date: [ ], 2025</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">Initial Exercise Date: [ ], 2025</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES F COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,&nbsp;[ ]&nbsp;or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the Termination Date (as defined herein) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Termination Date</u>&#8221; means the five (5) year anniversary of the Initial Exercise Date, provided, however, that if (i) the Holder&#8217;s Series G Common Stock Purchase Warrants (as such term is defined in that certain Securities Purchase Agreement, dated as of May 7, 2025, by and between the Company and the purchasers signatory thereto) has not been terminated in accordance with its terms prior to the date thirty (30) calendar days after the U.S Food and Drug Administration acceptance of the Company&#8217;s Investigational New Drug for an in-house obesity treatment compound (long-acting peptide or oral small molecule)(the &#8220;<u>FDA Exercise Period</u>&#8221;) and (ii) the Holder does not exercise such Series G Common Stock Purchase Warrants in full prior to the end of the FDA Exercise Period, the Termination Date shall mean the Trading Day immediately following the expiration of the FDA Exercise Period.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong> </strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $0.30, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:12%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Name:</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Title:</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series F Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:left;">To: </p></td> <td> <p style="MARGIN: 0px; text-align:left;"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Name:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Please Print)</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Address:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Phone Number:</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">E-mail Address: </p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dated: _______________ __, ______</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ptn_ex42.htm
<DESCRIPTION>SERIES G COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex42.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES G COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant Shares: [&#8226;]</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Issue Date: [ ], 2025</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Initial Exercise Date: [ ], 2025</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES G COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,&nbsp;[ ]&nbsp;or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the Termination Date (as defined herein) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Termination Date</u>&#8221; means the earlier of (i) the twenty-four (24) month anniversary of the Initial Exercise Date, and (ii) the 31<sup style="vertical-align:super">st</sup> calendar day following the date the Company receives the U.S Food and Drug Administration acceptance of the Company&#8217;s Investigational New Drug for an in-house obesity treatment compound (long-acting peptide or oral small molecule), provided that, if such date is not a Trading Day, the Termination Date shall be the immediately following Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong>&nbsp;</strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $0.15, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:10%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Name:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series G Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">To: </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phone Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail Address: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dated: _______________ __, ______</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">15</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>ptn_ex43.htm
<DESCRIPTION>SERIES H COMMON WARRANT
<TEXT>
<html><head><title>ptn_ex43.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF SERIES H COMMON STOCK PURCHASE WARRANT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Warrant Shares: [&#8226;]</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Issue Date: [&#8226;]</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Initial Exercise Date: [&#8226;]</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">THIS SERIES H COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received,&nbsp;[ ]&nbsp;or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date above, and on or prior to 5:00 p.m. (New York City time) on the twenty-four (24) month anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, the immediately following Trading Day (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to&nbsp;[ ]&nbsp;shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one Warrant Share shall be equal to the Exercise Price, as defined in Section 2(b). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 1</u>. <u>Definitions</u>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the Securities and Exchange Commission. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Equiniti Trust Company, LLC, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 2</u>. <u>Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<strong>&nbsp;</strong>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <strong>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be $0.225, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<u>Bloomberg</u>&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 135pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;"><u>&#8220;Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Mechanics of Exercise</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 3</u>. <u>Certain Adjustments</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<u>Black Scholes Value</u>&#8221; means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#8220;Company&#8221; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Notice to Holder</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; TEXT-INDENT: 33.75pt; text-align:justify;">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by e-mail to the Holder at its last e-mail address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 4</u>. <u>Transfer of Warrant</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>Transferability</u>. Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Section 5</u>. <u>Miscellaneous</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Authorized Shares</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Notices</u>. Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 4B Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Chief Executive Officer, e-mail address: cspana@palatin.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">********************</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Page Follows)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:5%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:10%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"></td> <td></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Name:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Title:</p></td> <td></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page to Series H Common Stock Purchase Warrant of </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>Palatin Technologies, Inc.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">To: </p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>PALATIN TECHNOLOGIES, Inc.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 1in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 101.25pt; text-align:justify;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">[SIGNATURE OF HOLDER]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Investing Entity: ________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Investing Entity</em>: _________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: ___________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ____________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: ________________________________________________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ASSIGNMENT FORM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:35%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address:</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phone Number:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail Address: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Please Print)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">______________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dated: _______________ __, ______</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Signature:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holder&#8217;s Address:<u>&nbsp;</u></p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>ptn_ex101.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<html><head><title>ptn_ex101.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES PURCHASE AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">This Securities Purchase Agreement (this &#8220;<u>Agreement</u>&#8221;) is dated as of May 7, 2025, between Palatin Technologies, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<u>Purchaser</u>&#8221; and collectively the &#8220;<u>Purchasers</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE I.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">DEFINITIONS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Acquiring Person</u>&#8221; shall have the meaning ascribed to such term in Section 4.5.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Action</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(j).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Auditor</u>&#8221; means KPMG LLP, an independent registered public accounting firm.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>BHCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(mm).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <u>provided</u>, <u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Closing</u>&#8221; means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Closing Date</u>&#8221; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount, and (ii) the Company&#8217;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1<sup style="vertical-align:super">st</sup>) Trading Day following the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Stock</u>&#8221; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Warrants</u>&#8221; means the Series F Common Warrants, Series G Common Warrants and Series H Common Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Common Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Common Warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Company Counsel</u>&#8221; means Thompson Hine LLP, with offices located at 300 Madison Avenue, 27th Floor, New York, NY 10017-6232.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Disclosure Time</u>&#8221; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agents, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Disqualification Event</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(qq).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Evaluation Date</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(s).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Exempt Issuance</u>&#8221; means the issuance of: (a) shares of Common Stock or options to employees, consultants, contractors, advisors, officers or directors of the Company pursuant to any stock or option plan or arrangement duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, provided that issuances to consultants under this clause (a) shall be issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein; (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, warrants to the Placement Agents in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to the Placement Agents and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities; and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FCPA</u>&#8221; means the Foreign Corrupt Practices Act of 1977, as amended.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FDA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>FDCA</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>GAAP</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Indebtedness</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(aa).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Intellectual Property Rights</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Issuer Covered Person</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(qq).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Issuer Free Writing Prospectus</u>&#8221; shall have the meaning ascribed to such term in Rule 433 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Legend Removal Date</u>&#8221; shall have the meaning ascribed to such term in Section 4.1(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Liens</u>&#8221; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Lock-Up Agreements</u>&#8221; means the lock-up agreements, each dated as of the date hereof in substantially the form of Exhibit A.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Material Adverse Effect</u>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Material Permits</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(n).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Money Laundering Laws</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(nn).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>OFAC</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(kk).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Per Share Purchase Price</u>&#8221; equals $0.15, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Per Pre-Funded Warrant Purchase Price</u>&#8221; means the Per Share Purchase Price minus $0.0001.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pharmaceutical Product</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Placement Agency Agreement</u>&#8221; means that certain Placement Agency Agreement by and between the Company and the Placement Agents, dated as of the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Placement Agents</u>&#8221; means A.G.P./Alliance Global Partners and Laidlaw &amp; Company (U.K.) Ltd.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pre-Funded Warrant Shares</u>&#8221; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Pre-Funded Warrants</u>&#8221; means, collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.3(a) hereof, in substantially the form of <u>Exhibit B</u> attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Preliminary Prospectus</u>&#8221; means the preliminary prospectus included in the Registration Statement at the time the Registration Statement is declared effective.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Proceeding</u>&#8221; means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Prospectus</u>&#8221; means the final prospectus filed for the Registration Statement, including all information, documents and exhibits filed with or incorporated by reference into such Prospectus. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Purchaser Party</u>&#8221; shall have the meaning ascribed to such term in Section 4.8.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Registration Statement</u>&#8221; means the effective registration statement on Form S-1, as amended (File No. 333-286280), filed with the Commission, including all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Shares, Common Warrants, Common Warrant Shares, Pre-Funded Warrants and Pre-Funded Warrant Shares to the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Required Approvals</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Rule 424</u>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>SEC Reports</u>&#8221; shall have the meaning ascribed to such term in Section 3.1(h).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Securities</u>&#8221; means the Shares, the Warrants and the Warrant Shares purchased pursuant to this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series F Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise equal to five (5) years following the Initial Exercise Date (as defined in the Series F Common Warrants), substantially in the form of Exhibit C attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series G Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise until the earlier of (i) the twenty four (24) month anniversary of the original issuance date or (ii) thirty (30) calendar days after the FDA acceptance of the Company&#8217;s Investigational New Drug (&#8220;IND&#8221;) for any obesity-related compound, substantially in the form of Exhibit D attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Series H Common Warrants</u>&#8221; means the Common Stock purchase warrants delivered to the Purchasers upon exercise of the Series G Common Warrants,&nbsp; which warrants shall be exercisable commencing on the date of their issuance and have a term of exercise until the twenty-four (24) month anniversary of the original issuance date, substantially in the form of Exhibit E attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Shares</u>&#8221; means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Short Sales</u>&#8221; means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Subscription Amount</u>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares (or Pre-Funded Warrants in lieu of Shares) and Common Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available funds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means a day on which the principal Trading Market is open for trading.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Transaction Documents</u>&#8221; means this Agreement, the Warrants, the Lock-Up Agreements, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means American Stock Transfer &amp; Trust Company, the current transfer agent of the Company, with a mailing address of 6201 15th Avenue, Brooklyn, New York 11219, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Variable Rate Transaction</u>&#8221; shall have the meaning ascribed to such term in Section 4.12(b).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market but it is quoted on the OTCQB Venture Market (&#8220;<u>OTCQB</u>&#8221;) or the OTCQX Best Market (&#8220;<u>OTCQX</u>&#8221;), the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted on a Trading Market, the OTCQB, or the OTCQX but if prices for the Common Stock are then reported in the Pink Open Market operated by the OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Warrants</u>&#8221; means, collectively, the Common Warrants and Pre-Funded Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">&#8220;<u>Warrant Shares</u>&#8221; means the Common Warrant Shares and Pre-Funded Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE II.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PURCHASE AND SALE</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.1 <u>Closing</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 63pt; text-align:justify;">(a) On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, an aggregate of $1.1 million of Shares and Warrants; provided, however, that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&#8217;s Affiliates, and any Person acting as a group together with such Purchaser or any of such Purchaser&#8217;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, in lieu of purchasing Shares, such Purchaser may elect to purchase Pre-Funded Warrants at the Per Pre-Funded Warrant Purchase Price in lieu of Shares. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. Each Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agents, settlement of the Shares shall occur via DVP<em>&nbsp;</em>(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agents identified by each Purchaser; upon receipt of such Shares, the Placement Agents shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agents (or its clearing firm) by wire transfer to the Company).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 63pt; text-align:justify;">(b) Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#8220;<u>Pre-Settlement Period</u>&#8221;), such Purchaser sells to any Person all, or any portion, of the Securities to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<u>Pre-Settlement Securities</u>&#8221;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Securities to such Purchaser at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Securities to such Purchaser prior to the Company&#8217;s receipt of the Subscription Amount for such Pre-Settlement Securities hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Warrants) for purposes hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.2 <u>Deliveries</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(a) On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) this Agreement duly executed by the Company;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) a legal opinion of Company Counsel, directed to the Placement Agents and the Purchasers, in a form reasonably acceptable to the Placement Agents and Purchasers; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the Company shall have provided each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iv) subject to Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) a Series F Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $0.30 subject to adjustment therein; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.85pt; TEXT-INDENT: 33.75pt; text-align:justify;">(vi) a Series G Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $0.15 subject to adjustment therein;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.85pt; TEXT-INDENT: 35.65pt; text-align:justify;">(vii) if applicable, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to equal to the portion of such Purchaser&#8217;s Subscription Amount applicable to Pre-Funded Warrants divided by the Per Pre-Funded Warrant Purchase Price, with an exercise price equal to $0.0001, subject to adjustment therein; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(viii) Lock-Up Agreements, in form and substance reasonably acceptable to the Placements Agents and the Purchasers, executed by each executive officer and director; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ix) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) this Agreement duly executed by such Purchaser; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) such Purchaser&#8217;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.7pt; text-align:justify;">(c) At the time this Agreement is executed, the Placement Agents shall have received from the Auditor a cold comfort letter containing statements and information of the type customarily included in accountants&#8217; comfort letters with respect to the financial statements and certain financial information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus, or any Issuer Free Writing Prospectus, addressed to the Placement Agents and in form and substance reasonably satisfactory to the Placement Agents, dated as of the date of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.7pt; text-align:justify;">(d) On the Closing Date, the Placement Agents shall have received from the Auditor a letter, dated as of the Closing Date, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant to Section 2.2(c)(i).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.7pt; text-align:justify;">(e) Upon the exercise of the Series G Common Warrants issued to the Purchasers in accordance with Section 2.2(a)(vi) hereof, the Company shall deliver or cause to be delivered to any Purchaser that exercises such Series G Common Warrants, a Series H Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares plus the Pre-Funded Warrant Shares, with an exercise price equal to $0.225 subject to adjustment therein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">2.3 <u>Closing Conditions</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 67.5pt; text-align:justify;">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(iv) there shall have been no Material Adverse Effect with respect to the Company; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 67.5pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE III.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">REPRESENTATIONS AND WARRANTIES</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">3.1 <u>Representations and Warranties of the Company</u>. Except as set forth in the SEC Reports, the Company hereby makes the following representations and warranties to each Purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;Material Adverse Effect&#8221;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus, (iii) the notice and/or application(s) to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (iv) such filings as are required to be made under applicable state securities laws (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(f) Issuance of the Securities; Registration. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrants are duly authorized and, when issued in accordance with this Agreement, will be duly and validly issued and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms free and clear of all Liens imposed by the Company. The Warrant Shares are duly authorized, and when issued against the payment of any applicable exercise price in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which Registration Statement was declared effective on May 6, 2025, including the Preliminary Prospectus, Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Preliminary Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Preliminary Prospectus, the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(g) Capitalization. The capitalization of the Company is as set forth in the SEC Reports as of the date set forth in such SEC Reports, including the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date indicated in such SEC Reports. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other (i) than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act, and (ii) securities issued pursuant to that that certain Securities Purchase Agreement entered into between the Company and such purchaser on February 6, 2025 (the &#8220;<u>February 6, 2025 SPA</u>&#8221;). No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<u>SEC Reports</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<u>GAAP</u>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(j) Litigation. Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(k) Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(l) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of clauses (i) through (iii), such as could not, have or reasonably be expected to result in a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(m) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(n) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(o) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(p) Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &#8220;Intellectual Property Rights&#8221;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(q) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(r) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(s) Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms. The Company&#8217;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;Evaluation Date&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(t) Certain Fees. Except for fees payable by the Company to the Placement Agents, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(u) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(v) Registration Rights. Except for the rights granted to the purchaser pursuant to the February 6, 2025 SPA, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(w) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(x) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(y) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(z) No Integrated Offering. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of the Warrants or the Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(aa) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. All outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments is set forth in the SEC Reports. For the purposes of this Agreement, &#8220;Indebtedness&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(bb) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(cc) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(dd) Accountants. The Company&#8217;s independent registered public accounting firm is KPMG LLP. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act, and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending June 30, 2025. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ee) Acknowledgment Regarding Purchasers&#8217; Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Securities. The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ff) Acknowledgment Regarding Purchaser&#8217;s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(gg) Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agents pursuant to the Placement Agency Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(hh) FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<u>FDA</u>&#8221;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#8220;<u>FDCA</u>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &#8220;<u>Pharmaceutical Product</u>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ii) Cybersecurity. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(jj) Stock Option Plans. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(kk) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;OFAC&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(ll) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#8217;s request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(mm) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;BHCA&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;Federal Reserve&#8221;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(nn) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;Money Laundering Laws&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">3.2 <u>Representations and Warranties of the Purchasers</u>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(b) Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(c) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(e) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agents nor any Affiliate of the Placement Agents has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither of the Placement Agents nor any Affiliate of the Placement Agents has made or makes any representation as to the Company or the quality of the Securities and the Placement Agents and any Affiliate of the Placement Agents may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of the Securities to such Purchaser, neither of the Placement Agents nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(f) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.75pt; TEXT-INDENT: 33.75pt; text-align:justify;">(g) No Conflicts. The execution, delivery and performance by each Purchaser of the Transaction Documents and the consummation by the Purchasers of the transactions contemplated thereunder will not (a) result in a violation of the organizational documents of a Purchaser or (b) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Purchaser is a party, or (c) result in a violation of any applicable law, rule, regulation, order, judgment or decree (including federal and state securities laws), except in the case of clauses (b) and (c) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of a Purchaser to perform its obligations hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE IV.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OTHER AGREEMENTS OF THE PARTIES</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.1 <u>Legends</u>. The Shares and, if all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares shall be issued free of all restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the initial sale by the Company of the Shares, the Warrants or the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the initial sale by the Company of the Shares, the Warrants or the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Shares, the Warrants or the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement) registering the issuance of the Warrant Shares effective during the term of the Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.2 <u>Furnishing of Information</u>. Until the earlier of the time that (i) no Purchaser owns Securities, or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.3 <u>Integration</u>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Warrants, Warrant Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.4 <u>Securities Laws Disclosure; Publicity</u>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law or the rules of any Trading Market, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of the final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.5 <u>Shareholder Rights Plan</u>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;Acquiring Person&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.6 <u>Non-Public Information</u>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agents, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.7 <u>Use of Proceeds</u>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and for any purposes set forth in the Prospectus, and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices or debt outstanding as of the date hereof in accordance with the terms in effect as of the date hereof), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.8 <u>Indemnification of Purchasers</u>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<u>Purchaser Party</u>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity (including a Purchaser Party&#8217;s status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of the Company who is not an Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the Transaction Documents, or (c) in connection with any registration statement of the Company providing for the resale by the Purchasers of the Warrant Shares issued and issuable upon exercise of the Warrants, the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses, as incurred, arising out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. For the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims brought by the Company against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage or liability to the extent it is finally judicially determined to be attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by a Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and, except with respect to direct claims brought by the Company, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal counsel), a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect amounts due under any Transaction Documents or to enforce the provisions of any Transaction Documents, then the Company shall pay the costs incurred by such Purchaser Party for such collection, enforcement or action, including, but not limited to, attorneys' fees and disbursements. The indemnification and other payment obligations required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation, defense, collection, enforcement or action, as and when bills are received or are incurred; provided, that if any Purchaser Party is finally judicially determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.9 <u>Reservation of Common Stock</u>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.10 <u>Listing of Common Stock</u>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.11 [Reserved.] </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.85pt; text-align:justify;">4.12 <u>Subsequent Equity Sales</u>. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(a) From the date hereof until forty-five (45) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents other than any sale of shares of Common Stock pursuant to the Company&#8217;s existing &#8220;at the market&#8221; offering under that certain Sales Agreement by and between the Company and A.G.P./Alliance Global Partners dated February 11, 2025 (the &#8220;<u>A.G.P. ATM Facility</u>&#8221;), or (ii) file any registration statement or amendment or supplement thereto, other than (x) the Prospectus, (y) a registration statement on Form S-8 in connection with any employee benefit plan, or (z) a prospectus supplement in connection with the A.G.P. ATM Facility.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(b) From the date hereof until the date four (4) months after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;<u>Variable Rate Transaction</u>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price; <u>provided</u>, <u>however</u>, that, after fifteen (15) days following the Closing Date, the issuance of shares of Common Stock in an &#8220;at the market&#8221; offering under the A.G.P. ATM Facility shall not be deemed a Variable Rate Transaction and the Company may file any related prospectus supplement thereto. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 33.85pt; TEXT-INDENT: 33.85pt; text-align:justify;">(c) Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.13 <u>Equal Treatment of Purchasers</u>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.14 <u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates, or agents, including, without limitation, the Placement Agents, after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.15 <u>Capital Changes</u>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.16 <u>Exercise Procedures</u>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">4.17 <u>Lock-Up Agreements</u>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements without the prior written consent of the Placement Agents, except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE V.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">MISCELLANEOUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.1 <u>Termination</u>. This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align:super">th</sup>) Trading Day following the date hereof; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.2 <u>Fees and Expenses</u>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.3 <u>Entire Agreement</u>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.4 <u>Notices</u>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align:super">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.5 <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.6 <u>Headings</u>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.7 <u>Successors and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.8 <u>Third-Party Beneficiaries</u>. The Placement Agents shall be the third party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.9 <u>Governing Law</u>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.10 <u>Survival</u>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.11 <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.12 <u>Severability</u>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.13 <u>Rescission and Withdrawal Right</u>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to acquire such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.14 <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.15 <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.16 <u>Payment Set Aside</u>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.17 <u>Independent Nature of Purchasers&#8217; Obligations and Rights</u>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through the legal counsel of the Placement Agents. The legal counsel of the Placement Agents does not represent any of the Purchasers and only represents the Placement Agents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.18 <u>Liquidated Damages</u>. The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.19 <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.20 <u>Construction</u>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">5.21<strong> <u>WAIVER OF JURY TRIAL</u>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>(Signature Pages Follow)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2"> <p style="MARGIN: 0px; text-align:left;"><strong>Palatin Technologies, Inc. </strong></p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;"><u>Address for Notice:</u></p></td></tr> <tr style="height:15px"> <td style="width:3%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">E-Mail:</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Name:</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">Title:</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">With a copy to (which shall not constitute notice):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[COMPANY SIGNATURE PAGE TO PTN SECURITIES PURCHASE AGREEMENT]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[PURCHASER SIGNATURE PAGES TO PTN SECURITIES PURCHASE AGREEMENT]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Purchaser: ______________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Signature of Authorized Signatory of Purchaser</em>: _________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: _______________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: ________________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail Address of Authorized Signatory: _________________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address for Notice to Purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Address for Delivery of Securities to Purchaser (if not same as address for notice):</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subscription Amount: $_________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Shares: _________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series F Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series G Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series H Common Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">EIN Number: ____________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the first (1<sup style="vertical-align:super">st</sup>) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit A</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Lock-Up Agreement</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit B</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Pre-Funded Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit C</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series F Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">31</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit D</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series G Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;text-align:center;">32</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit E</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Form of Series H Common Warrant</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>ptn_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>ptn_ex992.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.1in; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.1in; text-align:center;"><strong>Palatin Technologies Announces Transition to OTC Pink Following</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NYSE American Delisting Notice</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.1in; text-align:center;"><em id="del_eme67b10c9-99d7-49c8-b134-2f8900c73c6a">The Company Intends to Request a Review of the Delisting Determination</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.1in; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">CRANBURY, NJ &#8211; May 7, 2025 &#8211; Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC (&#8220;NYSE American&#8221;) stating that the NYSE Regulation has determined to commence proceedings to delist Palatin&#8217;s common stock. The notice, issued under Section 1003(f)(v) of the NYSE American Company Guide, cites the low selling price of Palatin&#8217;s common stock as the basis for delisting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">As a result, trading of Palatin&#8217;s common stock on the NYSE American has been immediately suspended, and the shares will transition to the OTC Pink Market under the ticker symbol &#8220;PTNT&#8221; beginning on May 8, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Palatin intends to appeal the delisting decision, although there can be no assurance that any such appeal will be successful. The Company has until May 14, 2025 to appeal the NYSE American&#8217;s decision.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">&#8220;We are disappointed with the delisting determination,&#8221; said Carl Spana, Ph.D., President and CEO of Palatin Technologies. &#8220;We continue to believe the Company has valuable assets and the actions of NYSE American will in no way deter our commitment to advance our business plan and increase stockholder value.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><u id="del_u80e8e4f7-abfa-409f-acaa-89cc03d4a57a">Forward-looking Statements</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the transition of the Company&#8217;s common stock to the OTC Pink Market and the Company&#8217;s appeal of the NYSE American&#8217;s delisting determination, are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company&#8217;s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Investor Inquiries:</strong></p></td> <td style="vertical-align:top;"><strong>Media Inquiries:</strong></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen T. Wills, CPA, MST</p></td> <td style="vertical-align:top;">Paul Arndt, MBA, LifeSci Advisors</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">CFO/COO (609) 495-2200</p></td> <td style="vertical-align:top;">Managing Director (646) 597-6992</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Info@Palatin.com</p></td> <td style="vertical-align:top;">Paul@LifeSciAdvisors.com</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">###</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>8
<FILENAME>ptn_ex992.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>ptn_ex992.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="MARGIN: 0px; text-align:right;"><strong>&nbsp; EXHIBIT 99.2</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Palatin Technologies Announces Pricing of up to $23 Million Public Offering</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0in"><em>$11.5 Million&nbsp;Upfront with up to an Additional&nbsp;$11.5 Million&nbsp;Upon the Cash Exercise&nbsp;of the Milestone Related Warrants</em></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">CRANBURY, N.J.,&nbsp;May 7, 2025&nbsp;/PRNewswire/ &#8212; Palatin Technologies, Inc. (NYSE American: PTN) (&#8220;Palatin&#8221; or the &#8220;Company&#8221;), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its public offering with participation from new and existing healthcare focused institutional investors along with the Company&#8217;s Chief Executive Officer, Chief Financial Officer, and certain board members, including the Chair consisting of 76,666,667 shares of common stock (or common stock equivalents in lieu thereof) together with Series F warrants to purchase up to 76,666,667 shares of common stock (the &#8220;<strong>Series F Warrants</strong>&#8220;), Series G warrants to purchase up to 76,666,667 shares of common stock (the &#8220;<strong>Series G Warrants</strong>&#8220;), and Series H warrants to purchase up to 76,666,667 shares of common stock (the &#8220;<strong>Series H Warrants</strong>&#8220;), at a combined public offering price of&nbsp;$0.15&nbsp;per share of common stock and accompanying warrants (the &#8220;<strong>Offering</strong>&#8220;).</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The Series F Warrants will have an exercise price of&nbsp;$0.30&nbsp;per share, will be immediately exercisable and will expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants will have an exercise price of&nbsp;$0.15&nbsp;per share, will be immediately exercisable and will expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of&nbsp;$0.225&nbsp;per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The closing of the Offering is expected to occur on or about&nbsp;May 8, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately&nbsp;$11.5 million. The Company may receive additional proceeds of up to&nbsp;$11.5 million&nbsp;upon the cash exercise of the milestone related Series G Warrants, however, there is no guarantee such warrants will be exercised and accordingly that the Company will receive any proceeds from the exercise thereof. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes, including for development work on its obesity program.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">A.G.P./Alliance Global Partners is acting as lead placement agent for the Offering and Laidlaw &amp; Company (UK) Ltd. is acting as co-placement agent for the Offering.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">A registration statement on Form S-1, as amended (File No. 333-286280), relating to the Offering was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on&nbsp;May 6, 2025. The Offering is being made only by means of a prospectus forming part of the effective registration statement relating to the Offering. A preliminary prospectus relating to the Offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC&#8217;s website at&nbsp;http://www.sec.gov&nbsp;and may also be obtained, when available, by contacting A.G.P./Alliance Global Partners at 590 Madison Avenue, 28th Floor,&nbsp;New York, NY&nbsp;10022, by phone at (212) 624-2060 or e-mail at&nbsp;prospectus@allianceg.com.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</em></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">1</p></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><u>About Palatin <p style="margin: 0px; text-align:justify;"> <p style="MARGIN: 0px; text-align:justify;"></p></u></strong>Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin&#8217;s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin&#8217;s website at&nbsp;www.Palatin.com&nbsp;and follow Palatin on Twitter at @PalatinTech. <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><u>Forward Looking Statements <p style="margin: 0px; text-align:justify;"> <p style="MARGIN: 0px; text-align:justify;"></p></u></strong>Statements in this press release that are not historical facts, including statements related to the timing and completion of the Offering, the potential exercise of the milestone related Series G Warrants, which may never occur, for additional gross proceeds to the Company of&nbsp;$11.5 million, the satisfaction of customary closing conditions related to the Offering and the intended use of proceeds therefrom, are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, market and other conditions; the anticipated use of proceeds from the Offering; results of clinical trials; regulatory actions by the FDA and other regulatory and the need for regulatory approvals; Palatin&#8217;s ability to fund development of its technology and establish and successfully complete clinical trials; the length of time and cost required to complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin&#8217;s products; and other factors discussed in Palatin&#8217;s periodic filings with the SEC. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Palatin Technologies<sup style="vertical-align:super">&#174;</sup>&nbsp;is a registered trademark of Palatin Technologies, Inc.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">SOURCE Palatin Technologies, Inc.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="margin:0px;height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="margin: 0px; text-align:center;">2</p></td></tr></table></p> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ptn-20250507.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/08/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ptn="http://ptn.com/20250507" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ptn.com/20250507">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://ptn.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250507_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250507_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250507_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250507_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
 <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
 <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
 <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
 <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
 <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
 <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ptn-20250507_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/08/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ptn-20250507_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/08/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250507.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ptn-20250507_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/08/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250507.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ptn-20250507_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/08/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250507.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PALATIN TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000911216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4078884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4B Cedar Brook Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">495-2200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $F+J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $F+J%H!AQC&[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !)BZA:1L=-2)4   #-    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $F+
MJ%H!AQC&[P   "L"   1              "  <,   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( $F+J%J97)PC$ 8  )PG   3              "
M >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 28NH6L^0HMT_
M!   ;Q   !@              ("!(@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( $F+J%J?H!OPL0(  .(,   -              "
M 9<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 28NH6I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  .L3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ptn_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptn-20250507.xsd</File>
    <File>ptn-20250507_cal.xml</File>
    <File>ptn-20250507_def.xml</File>
    <File>ptn-20250507_lab.xml</File>
    <File>ptn-20250507_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ptn_8k.htm">ptn_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ptn_8k.htm": {
   "nsprefix": "ptn",
   "nsuri": "http://ptn.com/20250507",
   "dts": {
    "schema": {
     "local": [
      "ptn-20250507.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptn-20250507_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptn-20250507_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptn-20250507_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptn-20250507_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ptn_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://ptn.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-05-07to2025-05-07",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-07to2025-05-07",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001654954-25-005296-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-005296-xbrl.zip
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M_E<1I'K@BA;T2.?(MJZI*<<+1[%5$IM&8_];VE,/8ND6F?D7UN=!L10(H_M
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MT.^XR^%FL&-QYF<:+K\#4$L#!!0    ( $F+J%K([^R1W $  (@#   4
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M1/%8^8YFUAG&7:,DV0QEI?_H,=LFML.A!Z83+C6Z=ZM=_@%02P,$%     @
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M7+#-3:5+P,]:N%'W5R46._6'OB>UH?QO-KOTU9JM=\/NHY*\[/*JT.WEUE1
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MO6N3VT:R-OA7L+/GTHR >M2ZC"_RZXBVU+*UQQ>]DCQSSFYL;( DV T+!&@
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MF;RAI')I+-)\WJ&Q"5;2"S+0W]=D;HYE+M%OZL!08K3C^RLS.ZHXOLSB4RS
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M5<Y14P*RTEOZ;ZX\B9H&P.I*YD?4VDI#G:0%>.,Q@@@0IG[DD?4P$H>F)^5
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M_,6"# ,.RTZIXTXR.5$50B*AROUH%P-EW-S<Y&$.D8TBG.K+TB&X#DPJMIT
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MJ],/M)@6Y6HB)C@YYR@/2IHUCY0OJ3W6OV.NN^(-:M&RN:ZZ5I\)*S.4$I7
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M=_Z ,9R2BV1?F,"AY[(QW6AEPY53W<[/[IW,F<K^'G:A4U]GU'S+;CXJRZ:
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M#=HPL^4JD-,=Z<845U3JT"R$*50S"8ZO*9J5504O9(JKZ537;BLW\,RA;+B
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M%T4"'Z8J'!T6==;9<RA8H*+W734'84+9217-T74I^XH(H]UQD\2=AO@/&6F
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M3A>,LZIW=-]2"CRQX8K[PH.UN-@LY08SBS:>'' 7'5K)7%J61"<E3*TX0M%
MI><)']P422O#]U^]R^W#A=%Z4UZ9/"88(2^+5\QYUL%4$\1GJ=Z32V2%]7O2
M]XSL7BUP<TZ@;7%ZP%M)RUFZ'X:8#3V#>O']J+L*6QH'31I;9"P2;CF7;BY3
M;\A]%66]\-]M3PY<PN-BTY^*1U%V%A(1=CY-.&JG3\WBD^J5QTL@)9;](B50
MTEYWO:DY\,:L9]Q6)X9L6V92)I')M5;/V_SC8G"\PWS'/6P[7](YWHI1Q;!3
M"L%N+^'VU8C%*M3W)9KV7=N WT!YOA6-@D)8](,G)3GE6 +YJ@/M%68DI65M
MCR<]A]P7=5ETC(9T+;AOA=W.=THP9*!O*WFEVT9AA.JV@:1RD?3SQ"Q\_'#,
MO9P^9V?9__-"C)'3__?C/VKWORQQ;+WT9#$(+(1-052Q?-1^9!-@2>@_3Y+0
M[YD0A&L\532M17INB68,38?=G17:D2</'L[@BEUOF%#D),^>$.GV/G8 !P5W
MM#,8NF3R//)7,++(1J"O*'/&)=VD:;>-!(<\54='K<ZHD,GR=XA%D;)L]P!+
M,P.\I3L(NGCB3C'!6*SOJ14$3H\V)&4G>TU:6\L97:,YU?I8SR0]AIB^V%O0
M<PZ/3A7:G9]^>_K\]*_GM= &?ENW\Z(F-Y^ 7$M*,3\MY]T6U^'L+,_NW;WW
M$+L"EP8?Q;?)SE_]D#T%U[FN0HR4SWXR<<\>_$9W6_(]MS-^\H9CYQ9O?;*;
M37,1*IC_Y9W/IY E"ER#.6O*%9A.6!C);_#/&1$;N3RY&=U$@7UB8CZVD^'=
M=,5\KZYPGZ[:+<SO@UD&6V6XFM87R9 ]K B1.!&G+#S+5T]0";)P2HJR"'6%
M@L\Q*:.ZX&#2H[?2$T1$:VN+,YH%1SW5KC O<]W6UPP0^SL\@IRQ%S@_)I!]
M:O;=Y$5F]Q%$%/%WECS-)4+LFSK]R@B0D@*Q6#]&0/^.T)G#SD(+7+029/\:
MFT=2.\@&=VDIT 3.(G7JIRMQZXAKPQ#U2YM.WPUR0IG*V7%R/F,R9!X$5_1T
MU0*/"0T.T-\\#$%,4&9&@Y;RO3:\8OP( 4>$8/^:%]P22I$Y3;_K!=_C?.+>
M5QJD1VYIC0U)F/#8CEBE)A> U=(W,P73^ADP[V[?.GQ/$X)EQEL,&@TXNAZ;
MG3#+/6_0WSQ*VD".,*M=L',O/^-T*?MY#@/+3)L.[SWJ*T<P*BEK1X='RU2B
MK*"L !^=;D'B_4JG$NF(7@2W5<JG>,](PY? WK@]L]/H?(#WQHU.J,,XJQ5_
MS-^!P=V1L>KY+ALX=]W5XB@Z6SIF/](VT&7SB0Y:]4=HQ&KF!/5#CA\(2H;_
M1KG(9:E7%?P'+(:3,[7A0O[ML5X.!"(M]Y3R?SO;)GF&ADE)H3G8HS-'\5*<
M/6.+L$"E3W:Q.V+,@SM];.Y(>&VKYA="M1,!>UV5JV3&!!,?MI$%0Y1D$C7[
MBK2QR]W>+([3G)I%%<#GD7DEB]GM!%%!XN[,MI7A*&+,')M=O,&8>/;,K8KB
M0XC'H-TC<1YX,KK+I_S6'Y??NO<IO_6>\Q!$[WR!S99!_LMBT !<7"?V(Z,
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M#"B2;I7?,*0YRGI'BCSW)"8IGE+U$M?1.P2!#1/[,7C0@KZ>J[ACDPU8&#X
M.(SEX46]'AM+#FHJ1&O-V$L7L-4%_-\^[X#_HU"?WEOUJ5EQ:P3]\=G1^>6I
M5ZC4Y@(V24,^5::<U1V@R8JDLJ1O<FL^-T7 K;B.7&OQ&A^HBF9K'/8!H:&
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MMK^=RV3W*R';$I<Y+BT_@R!)4I-(HSL(A=3TFYP$GQ47:=CL;M/@$[-H3 C
MUD'6*OYMRG8+E-K7R9?5Q.;J/FRM6F0Z'8@)71?2>^#@\2P;J)?:>YE"+K'_
MA_Y57W#D0F*S$9Z_1SU-ISH0Z_J4FZ2:ADNTJ"835>BMNQ2 642% L;7T;4:
M6H*WI(75< Z#T89I%@_8!-@ZM'.AP>8;E\ZDU C9T19CL77%"W=\BMSQL60!
MG5F&XO&:$?5R)8;#E[1QYT3T#6&I#19'4P-_C<[D;5AX7R42RR? [ S3K.3
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M$8;CS-_G)]9XZ@S$81C7LC'L ;CRUWN[I-"[' 1Q'4A]\>E\_:#_B*Y*>U[
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MVG(._YV"F"S$)0!2?3X&<:10&NM#Z9U%YPC*BV.@&6)991DZ'0BD9>0>(?V
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MI6>W46FPQM=Y#8<PIC8-4')W>H$3-\.1@;'%A"5=A2YISF04QF<T8]LM-&6
MKR TV#^8<NR86]/K5R_A&$WPK?42=HF\7+[ODK)Y#L/?!>&V_D^Z/G@&H;X4
M=""!NY$*YQ!4TB;P9WIPW:4L B>,P>77U+K6EP9?5TK!P8K&B0G C4+2?EXF
MWS68BJT1?ZUC$[M? Q8>[7I<[ZJGPZJ@TX$Z,$![VM9FRFQ;Z* O@7XR-[>4
MO-C76?^ED[[-QKF#AUG/2%T NB'C/Q_M?/OMG[[Y%O_W7YH2L5W5URIV)+V
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M]G8L^0")<"0>CBJW3A*"B\%EO<RH:(]DG?(90P>L&\.(Q0U(15TY2J]34VL
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MHTF_3P+^^N-0W8BX&Z3YY\8MW&$S^_%M,W2C)P>KEW_W_P%02P,$%     @
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M$]BZOU?UN^@P;_GMHT@6<P:+@8G@K/B%6TD3I=DT+T$+X5F.HO&RC<JJQ2^
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M"WJ3U0VQ"&2M:0XLM2U6R%^0;O);>UY7R]DY70#X9%[1;B#!LS1/:KKMP/-
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M:KV@!.RRI[ @0^(Q4?9'>4GPXOEBKZ%_EVN,'9620*X]+TQPB%@'IG2ONGI
M1.GS3%Y9B5 >CH)TPW$L%F?46$T&Z]>::Q"**%E434/5*UQ(*"^"HAC&_#'\
MU2B'I )DKC*#ER;/ G4F]QJ^P#THDDO)($7*4@AY?>%Q..P3Q%'CG#D@,$%G
M#%:AX=!8F7Y++_R- %045X*K,QURJGC^F*E5Z^3FZ3T?.*P]F1@.NW+X=5C1
M6;J?:)+[UZ=#LPI]4D4O:]8^L#*:$+&.3B=UOF!U&!Z9VD<:\PAV,%K8^DMX
M(KO/F8LI_-/T@AK*CB&_H&C=^CH7+]%1>IA1.R$W/QO9,)^N&C3D4B#V7;"
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M?@!V<5BEB'MBW*[P[E2H;UEBH0NNUCH8Y,ZR)":Q68JKQD\E=,,A'0AX6RE
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MP9/OET_IP]W'([C(L)/3'&;6GB5M'$VK.CI/"CB2=3;)\O,LC7FM_XC^R7^
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MS4E6((_6!\0B-B$?,;'5C-E2K7<YF62@+]4-&<(N:4#>@D8T&]T*J0J'IFS
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MA]S0Q/O@#PO!R>DA<]R2721T'.6U_ 993N4'K,-E^B,&]?N WZWF3N+28/+
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M/?!>/%NN[AU1[N\+V$$,$P-93F&T8J4TW<#)%=1<MI4XY0;;5)10)[_24S0
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M1_BZ_E:-5/#"%KI .O@Q9[Z"OYQE978NZE40E,9^UQI]]UL9]JE/P<4)>B+
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M,SZM<*42(1D3 (F)<V+[)(0-11Q]SRF#520701=+;:PH>HN->FY2JJ,FI50
M@_R&$:L[9K;2VX&;QK($1-,D5DDM[3.[<:A6T O8=G)!5MG4%,+S) IJU5@W
M>%9REX49IXWZK2LLM,'VW@R'](TA%T?Z,0TZ948T#1)X;5O59<;!#P;/^)TW
MJ6-FT&S3J=5I+($Y1YA5J.CC$L7D + A)W7]SJ=&19 8L,""^J2M+"=R6L>C
MY@]GV6"U:_UCT]?CE2F;L?8C?VZX)ZDYB[$V#& M2 HXBGWF_KWIT68<; 5:
ML$Z.L"T9R"6NU.:A1ZIP'0+=,#)\ )J.VEA3Z5)259 [11B-=X_Z%Y4HQ; 2
MXV!:A&B#G>R(-E1(I$:%UUW^;-4 )0E08O;:FY-?M#Q:E@5:F,Z[,7M7UQ3$
MY\%66Q9%; %1 \5E-AO:8.L1)[KUH!\CYML^SDAR!!M*3K!WEJYC,!!_'79C
MT.6@IN="U_.I+2QNZ.!CI[0?4JR88XOM)+ /'J8SV[Y9C%M- P_]JLH\SY)S
M1G2Z9Y&#%3?68?IIY2:/+0%,#TEGXTPG:+9*R/"@RKT"YF'SS[ B8I#2A,M6
MH:^F*D(2+-'3(,B]5X0,BPKU>A C6IE6.-RPFKBDRZ_,I7&VM]MO&O@PG[C-
MA,9:$6\TI:UD%#M-B(P@\<K\DY?LW&&G6A/5$MBI@O0[94, K<MZGQ.?2,\V
M]T 9/7L60Z=V.([WH924A3=N6KS3GSS5>E74NSTC-&TO ,8V^<*&U\APU=AT
M'K1&V661%9-D::U3::!]6^X]5\0+?9E#_6-K]77Z24=TT;55-!\>M-@%8A\4
MU."#E[3&[1B =_OF8O/D>]0;<6FI%&46P[A^JFE;T?_]Y>#5PQ YJPY8%$!>
MQ6-FYG6=0\@B.QF3,SOCJE)FT*Y#U4ODE,?4"=53YLWM3D>H4G3\LU--$ $Q
MCDTAQ4F[I!"1Z\)0I>6FG=]/LT0?&4OT==Z@>L<NJ=MG@QY76B,6SN>)T\C]
M)RH?ID'/QZ#[@G!J6V[Q@I?I(&G.>B1]6F7LO1>GFRL219A)R0P-UJ6F<X/Q
M ]=F2HG77;X?(*>>4/^NA U.;2& =+25CV*'V?<YW)Q?/-B.?G&M95']35S
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MB!T[7HCA@7$4T#L)"4B4(Z0AFA@E6/ODCH+_+S-K+]O?7G9DF"QF =ABYER
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MI+)[F-C%"2(I*NWKYOCM<H@'P"$*+N5#U72HDTBW=AI!I)UV :[DX(P8)U.
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M"1J,Q=E=!ACNV<J7^AA.N6[9!JU^ABEB<PY=QE66Y=A'8@A7GXOC?]#:,[Q
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MTZ<3S [A_T>3X,MOP/;V]ES,[!OTX=]02P,$%     @ 28NH6HMB94QO#
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M8?:A>T%"X6(EM)DB/N9*W[CKY86T\"YI/!.YT(Z7ZD)I@AB4YD(9L<2<Z.W
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M3^KGW5^R'?\/4$L! A0#%     @ 28NH6L<!U$F@!   %A<  !
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M2P$"% ,4    " !)BZA:F:WBA84$  #_(@  %               @ ':#P
M<'1N+3(P,C4P-3 W7W!R92YX;6Q02P$"% ,4    " !)BZA:*9]$@?D;  !#
MK@  "@              @ &1%   <'1N7SAK+FAT;5!+ 0(4 Q0    ( $F+
MJ%I)P%#(MY(   0F P -              "  ;(P  !P=&Y?97@Q,#$N:'1M
M4$L! A0#%     @ 28NH6FH+9(.M)P  I^$   P              ( !E,,
M '!T;E]E>#$Q+FAT;5!+ 0(4 Q0    ( $F+J%J..G:N3D0  +QM 0 ,
M          "  6OK  !P=&Y?97@T,2YH=&U02P$"% ,4    " !)BZA:2+.$
M+-A#  "/= $ #               @ 'C+P$ <'1N7V5X-#(N:'1M4$L! A0#
M%     @ 28NH6I&)3?E50P  )'0!  P              ( !Y7,! '!T;E]E
M>#0S+FAT;5!+ 0(4 Q0    ( $F+J%J@%]H8! <  * 7   -
M  "  62W 0!P=&Y?97@Y.3$N:'1M4$L! A0#%     @ 28NH6HMB94QO#
M*"<   T              ( !D[X! '!T;E]E>#DY,BYH=&U02P4&      T
,#0 7 P  +<L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>ptn_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptn-20250507.xsd" xlink:type="simple"/>
    <context id="From2025-05-07to2025-05-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2025-05-07</startDate>
            <endDate>2025-05-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2025-05-07to2025-05-07" id="ixv-467">0000911216</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2025-05-07to2025-05-07" id="ixv-468">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2025-05-07to2025-05-07" id="ixv-488">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2025-05-07to2025-05-07" id="ixv-489">2025-05-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2025-05-07to2025-05-07" id="ixv-490">PALATIN TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-05-07to2025-05-07" id="ixv-491">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2025-05-07to2025-05-07" id="ixv-492">001-15543</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-05-07to2025-05-07" id="ixv-493">95-4078884</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-05-07to2025-05-07" id="ixv-494">4B Cedar Brook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2025-05-07to2025-05-07" id="ixv-495">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-05-07to2025-05-07" id="ixv-496">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-05-07to2025-05-07" id="ixv-497">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-05-07to2025-05-07" id="ixv-498">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-05-07to2025-05-07" id="ixv-499">495-2200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2025-05-07to2025-05-07" id="ixv-500">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2025-05-07to2025-05-07" id="ixv-501">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2025-05-07to2025-05-07" id="ixv-502">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2025-05-07to2025-05-07" id="ixv-503">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2025-05-07to2025-05-07" id="ixv-504">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-05-07to2025-05-07" id="ixv-505">PTN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-05-07to2025-05-07" id="ixv-506">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-05-07to2025-05-07" id="ixv-507">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
